Advertisement

Picture Berlin Partner Top News from HealthCapital Berlin-Brandenburg 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2921 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Exscientia–Open Philanthropy: grant, 202312– grant $2.3m for research in host interferon response as therapeutic approach for pandemic influenza 2023-12-05
Freeline Therapeutics–Syncona: credit, 202311–202411 secured convertible loan note up to $15m with 12% interest + conversion price of $6.5/ADS 2023-11-22
Freeline Therapeutics–Syncona: investment, 202311– acquisition all remaining shares $6.5/ADS in going-private valuing entire issued capital at $28.3m 2023-11-22
Quotient Therapeutics–Flagship Pioneering: investment, 202311 Quotient Tx unveiled with initial $50m commitment from Flagship Pioneering 2023-11-21
T-Therapeutics–SEVERAL: investment, 202311 financing round Series A £48m 2023-11-15
Glox Therapeutics–SEVERAL: investment, 202311 seed financing round £4.3m led by BIVF + Scottish Enterprise 2023-11-14
ViaNautis Bio–4BIO Ventures: investment, 202311 financing round Series A totalling $25m incl co-lead investor 4BIO Capital 2023-11-13
ViaNautis Bio–BGF: investment, 202311 financing round Series A totalling $25m incl co-lead investor BGF 2023-11-13
ViaNautis Bio–Cystic Fibrosis Foundation: investment, 202311 financing round Series A totalling $25m incl co-investor Cystic Fibrosis Foundation 2023-11-13
ViaNautis Bio–Meltwind: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Meltwind 2023-11-13
ViaNautis Bio–o2h: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor O2H 2023-11-13
ViaNautis Bio–Origin Capital: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Origin Capital 2023-11-13
ViaNautis Bio–SEVERAL: investment, 202311 financing round Series A $25m led by 4BIO Capital + BGF + UCB Ventures 2023-11-13
ViaNautis Bio–UCB: investment, 202311 financing round Series A totalling $25m incl co-lead investor UCB Ventures 2023-11-13
Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV 2023-11-02
MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets 2023-10-30
AstraZeneca–Nanoform: drug delivery technology, 202310– license ww to Starmap Online 2023-10-23
GSK–Hansoh Pharmaceutical: antibody-drug conjugates, 202310– license ww excl Greater China to HS-20089 $85m upfront + $1.485b milestones + royalties 2023-10-20
Oxford Nanopore–Mérieux: investment, 202310 investment £69.1m purchase of 29m ordinary shares at £2.38/share by bioMérieux 2023-10-19
SpliceBio–Optimum Strategic Communications: public relations, 202310 service existent by Optimum 2023-10-17
AstronauTx–Optimum Strategic Communications: public relations, 202310 service existent by Optimum 2023-10-09
AstronauTx–SEVERAL: investment, 202310 financing round Series A ¯£48m led by Novartis Venture Fund 2023-10-09
United Kingdom (govt)–Siemens: PET/CT scanner, 202310–202304 supply 2 Biograph Vision Quadra PET/CT scanners by Siemens Healthineers to NPIP 2023-10-05
Mogrify–SEVERAL: investment, 202310 financing round Series A extension $10m bringing total Series A to $46m led by Astellas VM & Parkwalk Advisors 2023-10-02
Refeyn–Alto Marketing: public relations, 202310 service existent by Alto Marketing Ltd 2023-10-02
Laverock Therapeutics–Calculus Capital: investment, 202309 seed financing round totalling £13.5m incl lead investor Calculus Capital 2023-09-28
Laverock Therapeutics–Lilly: investment, 202309 seed financing round totalling £13.5m incl co-investor Eli Lilly 2023-09-28
Laverock Therapeutics–Mattioli Woods: investment, 202309 seed financing round totalling £13.5m incl co-investor Maven Capital Partners 2023-09-28
Laverock Therapeutics–Mercia: investment, 202309 seed financing round totalling £13.5m incl co-investor Mercia Ventures 2023-09-28
Laverock Therapeutics–SEVERAL: investment, 202309 seed financing round expansion to £13.5m led by Calculus Capital 2023-09-28
4SC–Optimum Strategic Communications: public relations, 202309 service existent by Optimum 2023-09-27
BioProtect–MVM: investment, 202309 financing round totalling $28m incl new + lead investor MVM Partners 2023-09-27
BioProtect–SEVERAL: investment, 202309 financing round $28m led by MVM Partners 2023-09-27
Crucible Therapeutics–Argobio: investment, 202309 financing round totalling £5m incl investor Argobio Studio 2023-09-25
Crucible Therapeutics–Northern Gritstone: investment, 202309 financing round totalling £5m incl investor Northern Gritstone 2023-09-25
Crucible Therapeutics–SEVERAL: investment, 202309 financing round £5m from Northern Gritstone + Argobio Studio 2023-09-25
Pepceuticals–Biosynth: investment, 202309 acquisition of Pepceuticals Ltd by Biosynth 2023-09-25
BenevolentAI–FTI Consulting: public relations, 202309 service existent by FTI Consulting 2023-09-20
Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront 2023-09-20
Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties 2023-09-20
Broken String Biosciences–Heran Partners: investment, 202309 financing round Series A totalling $15m incl new + co-investor Heran Partners 2023-09-18
Broken String Biosciences–Holtzbrinck: investment, 202309 financing round Series A totalling $15m incl existing + co-investor DvH Ventures 2023-09-18
Broken String Biosciences–Illumina: investment, 202309 financing round Series A totalling $15m incl new + co-lead investor Illumina Ventures 2023-09-18
Broken String Biosciences–Mérieux: investment, 202309 financing round Series A totalling $15m incl new + co-lead investor Mérieux Equity Partners 2023-09-18
Broken String Biosciences–SEVERAL: investment, 202309 financing round Series A $15m co-led by Illumina Ventures + Mérieux Equity Partners 2023-09-18
Broken String Biosciences–Tencent: investment, 202309 financing round Series A totalling $15m incl existing + co-investor Tencent 2023-09-18
Broken String Biosciences–Zyme Communications: public relations, 202309 service existent by Zyme 2023-09-18
Bastion Therapeutics–SEVERAL: investment, 202309 seed financing round $840k led by NG Bio 2023-09-12
Consilium–ICR: investment, 202309 acquisition of Consilium Strategic Communications by ICR 2023-09-12
Kuano–SEVERAL: investment, 202309 seed financing round £1.8m led by Mercia Ventures 2023-09-12
BioPharmics–Optibrium: investment, 202308 acquisition of BioPharmics LLC by Optibrium 2023-08-31
Intellegens–United Kingdom (govt): grant, 202308– 2y Innovate UK grant £1.6m to apply machine learning to manufacture of oligo drugs with CPI 2023-08-30
Intellegens–Zyme Communications: public relations, 202308 service existent by Zyme 2023-08-30
Abcam–Danaher: investment, 202308– acquisition $24/share in cash = enterprise value $5.7b incl assumed indebtedness + net of acquired cash 2023-08-28
Bit Bio–Synthego: gene editing, 202308– collab expansion applying gene editing to otpi-ox technology to engineer human cells for cell therapies 2023-08-24
Lindus Health–SEVERAL: investment, 202308 financing round Series A $18m led by Creandum 2023-08-16
NuChem Sciences–Sygnature Discovery: investment, acquisition of NuChem Sciences by Sygnature Discovery 2023-07-31
NK:IO–SEVERAL: investment, 202307 seed financing round extension £1.2m bringing total seed equity funding to £3.2m 2023-07-25
NK:IO–Zyme Communications: public relations, 202307 service existent by Zyme 2023-07-25
Crescendo Biologics–Andera Partners: investment, 202307 financing round totalling $32m incl existing investor Andera Partners 2023-07-24
Crescendo Biologics–BioNTech: investment, 202307 financing round totalling $32m incl existing investor BioNTech 2023-07-24
Crescendo Biologics–IP Group: investment, 202307 financing round totalling $32m incl existing investor IP Group 2023-07-24
Crescendo Biologics–Kreos Capital: investment, 202307 financing round totalling $32m incl new investor Kreos Capital 2023-07-24
Crescendo Biologics–Quan Capital: investment, 202307 financing round totalling $32m incl existing investor Quan Capital 2023-07-24
Crescendo Biologics–SEVERAL: investment, 202307 financing round $32m with new investor Kreos Capital + all major existing investors 2023-07-24
Crescendo Biologics–Sofinnova: investment, 202307 financing round totalling $32m incl existing investor Sofinnova Partners 2023-07-24
Crescendo Biologics–Takeda: investment, 202307 financing round totalling $32m incl existing investor Takeda 2023-07-24
Bicycle Therapeutics–SEVERAL: investment, 202307 public offering $200m+$30m with 6.1m+1.4m ADSs + non-voting ordinary shares at $21.25 each 2023-07-12
Tenpoint Therapeutics–F-Prime: investment, 202307 financing round Series A totalling $70m incl existing + co-lead investor F-Prime Capital 2023-07-12
Tenpoint Therapeutics–Fidelity: investment, 202307 financing round Series A totalling $70m incl existing + co-investor Eight Roads 2023-07-12
Tenpoint Therapeutics–Qiming: investment, 202307 financing round Series A totalling $70m incl existing + co-investor Qiming Venture Partners USA 2023-07-12
Tenpoint Therapeutics–SEVERAL: investment, 202307 financing round Series A $70m led by F-Prime Capital + Sofinnova Partners + British Patient Capital 2023-07-12
Tenpoint Therapeutics–Sofinnova: investment, 202307 financing round Series A totalling $70m incl existing + co-lead investor Sofinnova Partners 2023-07-12
Tenpoint Therapeutics–United Kingdom (govt): investment, 202307 financing round Series A totalling $70m incl new + co-lead investor BPC 2023-07-12
Tenpoint Therapeutics–Univ College London: investment, 202307 financing round Series A totalling $70m incl existing + co-investor UCL Technology Fund 2023-07-12
NK:IO–United Kingdom (govt): cell therapy manufacturing, 202307– collab developm manufacturing process for cell therapies with CGT Catapult 2023-07-11
NK:IO–United Kingdom (govt): grant, 202307– Innovate UK grant £1.6m from New Cancer Therapeutics programme 2023-07-11
Lario Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam 2023-07-05
Camena Bioscience–Mercia: investment, 202307 financing round Series A totalling $10m incl lead investor Mercia 2023-07-03
Camena Bioscience–SEVERAL: investment, 202307 financing round Series A $10m led by Mercia 2023-07-03
Camena Bioscience–Zyme Communications: public relations, 202307 service existent by Zyme 2023-07-03
MoonLake–Consilium: public relations, 202306 service existent by Consilium Strategic Communications 2023-06-28
Astraveus–Optimum Strategic Communications: public relations, 202306 service existent by Optimum 2023-06-27
AstraZeneca–SandboxAQ: AI-based drug discovery, 202306 collab existent disclosed of AZ with AQBioSim 2023-06-22
AstraZeneca–Quell Therapeutics: T cell therapy, 202306– collab developm $85m incl equity investment + >$2b milstones + royalties Tregs for T1D + IBD 2023-06-09
Quell Therapeutics–AstraZeneca: Investment, 202306 equity investment €na by AstraZeneca as part of collaboration 2023-06-09
Axol Bioscience–StrataStem: drug development technology, 202306– collab excl combining patient samples with iPSC technology for Alzheimer RnD 2023-06-07
OntoChem–Holtzbrinck: investment, 202306 acquisition 100% of OntoChem by Digital Science 2023-06-07
Theragnostics–Ariceum Therapeutics: investment, 202306 acquisition 100% of Theragnostics Ltd for $2.5m cash upfront plus $41.5m milestones 2023-06-01
eXmoor Pharma–Kineticos: investment, 202305 financing round Series A totalling $35m incl new investor Kineticos Ventures 2023-05-30
eXmoor Pharma–MVM: investment, 202305 financing round Series A totalling $35m incl existing investor MVM Partners 2023-05-30
eXmoor Pharma–SEVERAL: investment, 202305 financing round Series A $35m from Kineticos Ventures + MVM Partners 2023-05-30
Michor Consulting–QbD Group: investment, 202305 acquisition of Michor Consulting by QbD Group 2023-05-25
Renegade Therapeutics–F2 Ventures: investment, 202305 financing round Series A totalling $300m incl co-lead investor F2 Ventures 2023-05-23
Renegade Therapeutics–SEVERAL: investment, 202305 financing round Series A $300m led by MPM BioImpact + F2 Ventures 2023-05-23
Oncimmune–Freenome: investment, 202305 acquisition of Oncimmune Ltd by Freenome 2023-05-22
Dualyx–Consilium: public relations, 202305 service existent by Consilium Strategic Communications 2023-05-15
Dualyx–Fountain Healthcare Partners: investment, 202305 financing round Series A totalling €40m incl new + co-lead investor Fountain HP 2023-05-15
Dualyx–SEVERAL: investment, 202305 financing round Series A €40m co-led by Fountain Heathcare Partners + Forbion + Andera Partners 2023-05-15
Nido Biosciences–SEVERAL: investment, 202305c financing round Series B bringing total from seed + Series A + Series B to $109m 2023-05-15
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page



Advertisement

Picture Berlin Partner Voices from HealthCapital Charpentier 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Special Topic HealthCapital Berlin-Brandenburg 650x300px

» top